← 홈

Antibody · 건선

52개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 52개
AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleSamsung Bioepis Co., Ltd.Approved

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Approved#항체#면역항체+2
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNovartisApproved

Secukinumab Auto-Injector (Secukinumab Auto-Injector)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNovartisPhase 1

Secukinumab Auto-Injector [Cosentyx] (Secukinumab Auto-Injector [Cosentyx])

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleMoonLake Immunotherapeutics AGPhase 2

Sonelokimab (Sonelokimab)

Arthritis, Psoriatic · Arthritis, Psoriatic

#ArthritisPsoriatic#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

adalimumab (Humira, adalimumab and methotrexate)

Psoriasi · Psoriasi

#Psoriasi#Antibody#Preclinical#항체#면역항체+2
효능 ORR 6.35%임상시험 1상태 ACTIVE
AntibodystaleAbbViePreclinical

adalimumab (Humira, adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate)

Immunoclassification; Psoriasis · Immunoclassification

#Immunoclassification#Antibody#Preclinical#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJinnah Postgraduate Medical Cen…Preclinical

injection Sekucinumab (injection Sekucinumab)

Erythrodermic Psoriasis · Erythrodermic Psoriasis

#ErythrodermicPsoriasis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNovartisPhase 3

secukinumab high dose (secukinumab high dose)

Moderate to Severe Chronic Plaque-type Psoriasis · Moderate to Severe Chronic Plaque-type P

#ModeratetoSevereChronicPlaque-ty#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNovartisPhase 3

secukinumab low dose (secukinumab low dose)

Moderate to Severe Chronic Plaque-type Psoriasis · Moderate to Severe Chronic Plaque-type P

#ModeratetoSevereChronicPlaque-ty#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity Hospital, Gentofte, …Preclinical

adalimumab (Humira, subjects will receive either infliximab, adalimumab or etanercept)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE

3 / 3 페이지

← 이전다음 →